Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pontmestrocel (human primitive mesenchymal stem cells) for steroid-refractory chronic GVHD
CTR20230686Phase 3Active
- Sponsor
- Madison Regenerative Medicine
- Start
- Jul 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of pontmestrocel in steroid-refractory chronic graft-versus-host disease (SR-cGVHD), sponsored by Madison Regenerative Medicine. Started Jul 2023; status: active.
02
Drugs
pontmestrocel
03
Conditions
steroid-refractory chronic graft-versus-host disease (SR-cGVHD)
Beyond the preview
Go deeper on CTR20230686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230686.